PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
143.20
-3.80 (-2.59%)
As of 4:19PM IDT. Market open.
Stock chart is not supported by your current browser
Previous Close147.00
Open147.00
Bid143.30 x 128000
Ask146.70 x 209400
Day's Range143.10 - 145.00
52 Week Range108.00 - 276.70
Volume6,000
Avg. Volume112,268
Market Cap220.986M
Beta (3Y Monthly)2.38
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Associated Press17 days ago

    Protalix: 1Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 5 cents. The drug developer posted revenue of $10.4 million in the period. The company's shares closed at 44 cents. A year ...

  • Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks6 months ago

    Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Protalix: 3Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents. The drug developer posted revenue of $663,000 in the period. The company's shares closed at 49 cents. A year ago, ...

  • Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
    Zacks7 months ago

    Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know

    Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks9 months ago

    Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?
    Simply Wall St.9 months ago

    Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?

    In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...

  • Associated Press9 months ago

    Protalix: 2Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...

  • Benzinga10 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...